This study did not reveal statistically significant differences between the relative expression level of KRAS and HRAS genes in NSCLC patients at three points of time during the observation, thus it is not possible to use them as markers of the disease progression. This evidence concerns the gene HRAS and non-small cell lung carcinoma.